CUSIP: 30049G104
Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
1,997,512
-
Share change
-
-51,105
-
Total reported value
-
$987,030
-
Price per share
-
$0.49
-
Number of holders
-
18
-
Value change
-
-$33,393
-
Number of buys
-
6
-
Number of sells
-
10
Quarterly Holders Quick Answers
What is CUSIP 30049G104?
CUSIP 30049G104 identifies EVOK - EVOKE PHARMA INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q2 2022
-
Previous quarter:
Q4 2021
Recent filing periods for CUSIP 30049G104:
Institutional Holders of EVOKE PHARMA INC - COM (EVOK) as of Q1 2022
As of 31 Mar 2022,
EVOKE PHARMA INC - COM (EVOK) was held by
18 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,997,512 shares.
The largest 10 holders included
VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, BlackRock Inc., Raymond James Financial Services Advisors, Inc., STATE STREET CORP, Cornerstone Capital, Inc., Virtu Financial LLC, NORTHERN TRUST CORP, Wambolt & Associates, LLC, and RENAISSANCE TECHNOLOGIES LLC.
This page lists
18
institutional shareholders reporting positions in this security
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.